Inhibition of HDAC3 reverses Alzheimer’s disease-related pathologies in vitro and in the 3xTg-AD mouse model

Karolina J. Janczura, Claude Henry Volmar, Gregory Sartor, Jonnagadda S Rao, Natalie R. Ricciardi, Guerline Lambert, Shaun P Brothers, Claes R Wahlestedt

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Alzheimer’s disease (AD) is the leading cause of age-related dementia. Neuropathological hallmarks of AD include brain deposition of β-amyloid (Aβ) plaques and accumulation of both hyperphosphorylated and acetylated tau. RGFP-966, a brain-penetrant and selective HDAC3 inhibitor, or HDAC3 silencing, increases BDNF expression, increases histone H3 and H4 acetylation, decreases tau phosphorylation and tau acetylation at disease-associated sites, reduces β-secretase cleavage of the amyloid precursor protein (APP), and decreases Aβ142 accumulation in HEK-293 cells overexpressing APP with the double Swedish mutation (HEK/APPsw). In the triple transgenic AD mouse model (3xTg-AD), repeated administration of 3 and 10 mg/kg of RGFP-966 reverses pathological tau phosphorylation at Thr181, Ser202, and Ser396, increases levels of the Aβ degrading enzyme Neprilysin in plasma, decreases Aβ142 protein levels in the brain and periphery, and improves spatial learning and memory. Finally, we show that RGFP-966 decreases Aβ142 accumulation and both tau acetylation and phosphorylation at disease residues in neurons derived from induced pluripotent stem cells obtained from APOEe4-carrying AD patients. These data indicate that HDAC3 plays an important regulatory role in the expression and regulation of proteins associated with AD pathophysiology, supporting the notion that HDAC3 may be a disease-modifying therapeutic target.

Original languageEnglish (US)
Pages (from-to)E11148-E11157
JournalProceedings of the National Academy of Sciences of the United States of America
Volume115
Issue number47
DOIs
StatePublished - Nov 20 2018

Fingerprint

Alzheimer Disease
Pathology
Acetylation
Phosphorylation
Histones
Brain
Neprilysin
Induced Pluripotent Stem Cells
Amyloid Precursor Protein Secretases
Amyloid beta-Protein Precursor
HEK293 Cells
Brain-Derived Neurotrophic Factor
Amyloid Plaques
Dementia
Inhibition (Psychology)
In Vitro Techniques
Proteins
Neurons
Mutation
Enzymes

Keywords

  • Alzheimer’s disease
  • Epigenetics
  • HDACs
  • Histone deacetylase 3 inhibitor
  • Tau posttranslational modifications

ASJC Scopus subject areas

  • General

Cite this

Inhibition of HDAC3 reverses Alzheimer’s disease-related pathologies in vitro and in the 3xTg-AD mouse model. / Janczura, Karolina J.; Volmar, Claude Henry; Sartor, Gregory; Rao, Jonnagadda S; Ricciardi, Natalie R.; Lambert, Guerline; Brothers, Shaun P; Wahlestedt, Claes R.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 115, No. 47, 20.11.2018, p. E11148-E11157.

Research output: Contribution to journalArticle

@article{a1aabd282266438cb079cba838a80c11,
title = "Inhibition of HDAC3 reverses Alzheimer’s disease-related pathologies in vitro and in the 3xTg-AD mouse model",
abstract = "Alzheimer’s disease (AD) is the leading cause of age-related dementia. Neuropathological hallmarks of AD include brain deposition of β-amyloid (Aβ) plaques and accumulation of both hyperphosphorylated and acetylated tau. RGFP-966, a brain-penetrant and selective HDAC3 inhibitor, or HDAC3 silencing, increases BDNF expression, increases histone H3 and H4 acetylation, decreases tau phosphorylation and tau acetylation at disease-associated sites, reduces β-secretase cleavage of the amyloid precursor protein (APP), and decreases Aβ1–42 accumulation in HEK-293 cells overexpressing APP with the double Swedish mutation (HEK/APPsw). In the triple transgenic AD mouse model (3xTg-AD), repeated administration of 3 and 10 mg/kg of RGFP-966 reverses pathological tau phosphorylation at Thr181, Ser202, and Ser396, increases levels of the Aβ degrading enzyme Neprilysin in plasma, decreases Aβ1–42 protein levels in the brain and periphery, and improves spatial learning and memory. Finally, we show that RGFP-966 decreases Aβ1–42 accumulation and both tau acetylation and phosphorylation at disease residues in neurons derived from induced pluripotent stem cells obtained from APOEe4-carrying AD patients. These data indicate that HDAC3 plays an important regulatory role in the expression and regulation of proteins associated with AD pathophysiology, supporting the notion that HDAC3 may be a disease-modifying therapeutic target.",
keywords = "Alzheimer’s disease, Epigenetics, HDACs, Histone deacetylase 3 inhibitor, Tau posttranslational modifications",
author = "Janczura, {Karolina J.} and Volmar, {Claude Henry} and Gregory Sartor and Rao, {Jonnagadda S} and Ricciardi, {Natalie R.} and Guerline Lambert and Brothers, {Shaun P} and Wahlestedt, {Claes R}",
year = "2018",
month = "11",
day = "20",
doi = "10.1073/pnas.1805436115",
language = "English (US)",
volume = "115",
pages = "E11148--E11157",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "47",

}

TY - JOUR

T1 - Inhibition of HDAC3 reverses Alzheimer’s disease-related pathologies in vitro and in the 3xTg-AD mouse model

AU - Janczura, Karolina J.

AU - Volmar, Claude Henry

AU - Sartor, Gregory

AU - Rao, Jonnagadda S

AU - Ricciardi, Natalie R.

AU - Lambert, Guerline

AU - Brothers, Shaun P

AU - Wahlestedt, Claes R

PY - 2018/11/20

Y1 - 2018/11/20

N2 - Alzheimer’s disease (AD) is the leading cause of age-related dementia. Neuropathological hallmarks of AD include brain deposition of β-amyloid (Aβ) plaques and accumulation of both hyperphosphorylated and acetylated tau. RGFP-966, a brain-penetrant and selective HDAC3 inhibitor, or HDAC3 silencing, increases BDNF expression, increases histone H3 and H4 acetylation, decreases tau phosphorylation and tau acetylation at disease-associated sites, reduces β-secretase cleavage of the amyloid precursor protein (APP), and decreases Aβ1–42 accumulation in HEK-293 cells overexpressing APP with the double Swedish mutation (HEK/APPsw). In the triple transgenic AD mouse model (3xTg-AD), repeated administration of 3 and 10 mg/kg of RGFP-966 reverses pathological tau phosphorylation at Thr181, Ser202, and Ser396, increases levels of the Aβ degrading enzyme Neprilysin in plasma, decreases Aβ1–42 protein levels in the brain and periphery, and improves spatial learning and memory. Finally, we show that RGFP-966 decreases Aβ1–42 accumulation and both tau acetylation and phosphorylation at disease residues in neurons derived from induced pluripotent stem cells obtained from APOEe4-carrying AD patients. These data indicate that HDAC3 plays an important regulatory role in the expression and regulation of proteins associated with AD pathophysiology, supporting the notion that HDAC3 may be a disease-modifying therapeutic target.

AB - Alzheimer’s disease (AD) is the leading cause of age-related dementia. Neuropathological hallmarks of AD include brain deposition of β-amyloid (Aβ) plaques and accumulation of both hyperphosphorylated and acetylated tau. RGFP-966, a brain-penetrant and selective HDAC3 inhibitor, or HDAC3 silencing, increases BDNF expression, increases histone H3 and H4 acetylation, decreases tau phosphorylation and tau acetylation at disease-associated sites, reduces β-secretase cleavage of the amyloid precursor protein (APP), and decreases Aβ1–42 accumulation in HEK-293 cells overexpressing APP with the double Swedish mutation (HEK/APPsw). In the triple transgenic AD mouse model (3xTg-AD), repeated administration of 3 and 10 mg/kg of RGFP-966 reverses pathological tau phosphorylation at Thr181, Ser202, and Ser396, increases levels of the Aβ degrading enzyme Neprilysin in plasma, decreases Aβ1–42 protein levels in the brain and periphery, and improves spatial learning and memory. Finally, we show that RGFP-966 decreases Aβ1–42 accumulation and both tau acetylation and phosphorylation at disease residues in neurons derived from induced pluripotent stem cells obtained from APOEe4-carrying AD patients. These data indicate that HDAC3 plays an important regulatory role in the expression and regulation of proteins associated with AD pathophysiology, supporting the notion that HDAC3 may be a disease-modifying therapeutic target.

KW - Alzheimer’s disease

KW - Epigenetics

KW - HDACs

KW - Histone deacetylase 3 inhibitor

KW - Tau posttranslational modifications

UR - http://www.scopus.com/inward/record.url?scp=85056788613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056788613&partnerID=8YFLogxK

U2 - 10.1073/pnas.1805436115

DO - 10.1073/pnas.1805436115

M3 - Article

C2 - 30397132

AN - SCOPUS:85056788613

VL - 115

SP - E11148-E11157

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 47

ER -